28 October
2024
Avacta Group
plc
("Avacta"
or "the Group" or "the Company")
Block Listing Six Monthly
Return
Avacta
Group plc (AIM: AVCT), a life sciences company developing next
generation peptide drug conjugates (PDC) targeting powerful
anti-tumor payloads directly to the tumor, today
makes the following notification pursuant to
Schedule Six of the AIM Rules for Companies regarding its existing
block admission arrangements:
|
Name of applicant:
|
Avacta Group plc
|
|
Name of scheme:
|
EMI scheme
|
|
Period of return:
|
From:
|
28 April 2024
|
|
27 October 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
803,006
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
nil
|
|
Less: Number
of securities issued/allotted
under scheme(s) during period (see LR3.5.7G):
|
527,626
|
|
Equals: Balance under scheme(s)
not yet issued/allotted at end of period:
|
275,380
|
|
|
|
|
|
|
|
Name of applicant:
|
Avacta Group plc
|
|
Name of scheme:
|
LTIP scheme
|
|
Period of return:
|
From:
|
28 April 2024
|
|
27 October 2024
|
|
Balance of unallotted securities
under scheme(s):
|
9,719,257
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
nil
|
|
Less: Number
of securities issued/allotted
under scheme(s) during period (see LR3.5.7G):
|
3,806,000
|
|
Equals: Balance under scheme(s)
not yet issued/allotted at end of period:
|
5,913,257
|
|
|
|
|
|
|
|
Name of contact:
|
James Heseltine, Company
Secretary
|
|
Telephone number of
contact:
|
+ 44 (0) 1904 217070
|
Ends-
For further information
from Avacta Group plc, please contact:
About the pre|CISION® Platform
The
pre|CISION® platform comprises an anticancer
payload conjugated to a proprietary peptide that is a highly
specific substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumors compared with healthy tissues. The
pre|CISION® platform harnesses this tumor
specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the
tumor microenvironment, thus releasing active payload in the tumor
and reducing systemic exposure and toxicity, allowing dosing to be
optimized to deliver the best outcomes for patients.
About AVA6000: FAP-enabled doxorubicin
The lead
pre|CISION® program AVA6000, a peptide drug
conjugate form of doxorubicin, is in Phase 1 studies. It has shown
an improvement in safety and tolerability in clinical trials to
date compared with standard doxorubicin and preliminary signs of
clinical activity in multiple patients.To register for news alerts
by email go to https://avacta.com/investors/investor-news-email-alerts/.
AVA6103: FAP-enabled PDC targeting Topoisomerase
I
AVA6103 is a pre|CISION-enabled PDC
comprised of the pre|CISION peptide linked to exatecan, the most
potent topoisomerase I inhibitor in clinical development. Exatecan
has demonstrated clinical activity in breast, gastric, lung and
pancreatic cancers; however, it is associated with severe
dose-limiting toxicities and a short half-life in patients that led
to discontinuation of its monotherapy development. AVA6103 is
designed to enable patients to obtain the therapeutic benefit
associated with exatecan, while limiting the systemic exposure
associated with its poor tolerability.
AVA7100: pre|CISION® FAP Affimer Drug Conjugate
(AffDC)
AVA7100
is a pre|CISION®-enabled
Affimer® drug conjugate, a new class of therapies being developed
by Avacta with potential applications in a variety of
cancer types, including those with lower levels of FAP in the
tumor. Affimer® molecules are small
proteins that are engineered to bind to a target molecule in the
same way that an antibody does, but with several advantages,
including smaller molecule size and a broad range of binding
affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a
pre|CISION-peptide linker with multiple options for the
payload.
About Avacta Group plc - https://avacta.com/
Avacta Group is a UK-based
life sciences company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics. Its clinical
stage oncology biotech division Avacta Therapeutics is harnessing
the proprietary pre|CISION® platform technology to develop novel, highly targeted cancer
drugs. Avacta Diagnostics focuses on supporting healthcare
professionals and broadening access to diagnostics. To register for
news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/.